Appendix 2 (as supplied by the authors)

Basic characteristics by urate-lowering therapy exposure status			
Characteristics	Urate-lowering therapy unexposed N=15,661	Urate-lowering therapy exposed N= 15,661	Standardised difference *
Mean Age at urate-lowering therapy exposure (S.D.)	65.3 (14.1)	65.3 (14.1)	0.001
Male	11,834 (75.6)	11,834 (75.6)	0.000
Median follow-up after urate-lowering therapy (IQR)	3.3 (1.6-6.1)	4.5 (2.3-7.5)	0.121
Median time with gout before urate-lowering therapy (IQR)	1.9 (0.8-3.9)	1.08 (0.6-3.3)	-0.281
Body mass index			
Normal (18.5-24.9)	3391 (21.7)	2,497 (15.9)	0.238
Underweight (<18.5)	189 (1.2)	142 (0.9)	
Overweight (25.29.9)	6,067 (38.7)	5,819 (37.2)	
Obese (>30)	5,001 (31.9)	6,555 (41.9)	
Missing	1,013 (6.5)	648 (4.1)	
Smoking status			
Never/Ex-smoker	13,877 (88.6)	14,489 (92.5)	0.134
Current smokers	1,784 (11.4)	1,172 (7.5)	
Charlson index (IQR)			
0	6,092 (38.9)	4,923 (31.4)	-0.219
1-2	4,719 (30.1)	4,447 (28.4)	
3-4	2,789 (17.8)	3,167 (20.2)	
>5	2,061 (13.2)	3,124 (20.0)	
Deprivation			
1 (Least deprived)	4,014 (25.7)	3,357 (22.6)	0.084
2	3,904 (25.0)	3,878 (24.9)	
3	3,194 (20.4)	3,262 (20.9)	
4	2,679 (17.2)	2,829 (18.1)	
5 (Most deprived)	1,857 (11.9)	2,136 (13.7)	
Hypertension	5,196 (33.1)	6,271 (40.0)	0.143
Diabetes	1,683 (10.8)	2,212 (14.1)	0.103
Aspirin	4,389 (28.0)	5,255 (33.6)	0.120
Thiazides	5,150 (32.9)	5,864 (37.4)	0.09
Alcohol consumption			
Never/Ex-drinker	1,815 (11.6)	1,925 (12.3)	0.028
Current (<10 units/week)	6,340 (40.5)	6,364 (40,8)	
Current (≥10 units/week)	5,417 (34,6)	5,364 (34.3)	
Missing	2,089 (13,3)	1,986 (12.7)	
*Standardized difference = difference in means or proportion divided by standard error; imbalance defined as absolute value greater than 0.10 (small effect size).			